• <code id="ossuk"></code>
    • <li id="ossuk"></li>
    • <rt id="ossuk"></rt>
    • <rt id="ossuk"><tr id="ossuk"></tr></rt>
      <abbr id="ossuk"></abbr>
      <rt id="ossuk"><acronym id="ossuk"></acronym></rt>
      產品中心您現(xiàn)在的位置:首頁 > 產品展示 > 抗體 > 內參抗體 > InVivoMab anti-human PD-1 (CD279)

      InVivoMab anti-human PD-1 (CD279)

      更新時間:2022-01-27

      簡要描述:

      The J116 monoclonal antibody reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of……

      型號:廠商性質:代理商瀏覽量:994

      The J116 monoclonal antibody reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1's structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. Binding of the J116 antibody is reported to inhibit PD-1 signal transduction, however, it is not reported to block PD-L1 binding.


      產品名稱:InVivoMab anti-human PD-1 (CD279)

      反應種屬:human

      宿主來源:mouse

      實驗應用:in vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice

      同種型:IgG1, κ

      克隆性:Monoclonal

      克隆號:J116

      產品濃度:Lot specific,typically between 4-11 mg/ml

      保存溫度:Undiluted at 4°C in the dark

      運輸溫度:Ship with adequate amount of blue ice to ensure the product remains at 4°C for the duration of transit

      預期分子量:150 kDa

      產品形式:液體

      有效期:One year from the date of receipt if stored as recommended

      產地:美國



      如需購買或咨詢Bioxcell公司的產品,請聯(lián)系Bioxcell*代理商欣博盛生物


      留言框

      • 產品:

      • 您的單位:

      • 您的姓名:

      • 聯(lián)系電話:

      • 常用郵箱:

      • 省份:

      • 詳細地址:

      • 補充說明:

      • 驗證碼:

        請輸入計算結果(填寫阿拉伯數字),如:三加四=7
      91久久精品国产免费直播| 精品久久久无码人妻字幂| 久久狠狠一本精品综合网| 久久精品一区二区三区不卡| 久久久久久久久久久久中文字幕 | 久久九九国产精品怡红院| 久久亚洲色WWW成人欧美| 亚洲av伊人久久综合密臀性色| 美女久久久久久久久久久| 久久久2019精品| 国产精品美女久久久网AV| 久久精品国产99国产精品亚洲 | 伊人久久大香线蕉无码| 日本久久久精品中文字幕| 精品久久久久不卡无毒| 亚洲国产精品无码久久久秋霞2| 夜夜躁日日躁狠狠久久| 久久久国产打桩机| 亚洲精品乱码久久久久久自慰| 四虎国产精品免费久久| 久久久噜噜噜久久网| 大尺度视频网站久久久久久久久| 国产精品久久久香蕉| 青草国产精品久久久久久| 一本久久a久久精品亚洲| 精品乱码久久久久久中文字幕| 99久久久国产精品免费牛牛四川| 久久精品国产亚洲综合色| 一本色道久久88综合日韩精品| 久久久国产99久久国产一| 日韩精品久久无码中文字幕| 精品久久久久久久久中文字幕| 九九久久国产精品| 久久国产精品成人无码网站| 久久精品水蜜桃av综合天堂| 久久综合久久精品| 99久久777色| 国产精品免费久久| 色综合99久久久无码国产精品| 日产精品久久久久久久性色| 99久久精品全部|